Articles By Anuja Singh
Can GSK’s Gepotidacin Priority FDA Review and Strategic Acquisitions Accelerate Its Antibiotic and Specialty…
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
By
Why Is Eli Lilly’s 2025 Outlook Soaring Despite Orforglipron’s Late-Stage Trial Falling Short?
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R Inhibition, Revolutionize Treatment for Sjögren’s Disease?
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug Price Cuts Signal a New Era…
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
How Google Med-Gemini’s “Basilar Ganglia” AI Hallucination Signal a Wake-Up Call for Safer AI in Medical Diagnostics?
Key Highlights: AI Hallucination: The “Basilar Ganglia” ErrorGoogle’s Med-Gemini suite, designed to summarize health data and generate radiology…
Can XtalPi & DoveTree’s $6 Billion AI Partnership Transform “Undruggable” Disease Targets in Biopharma…
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…
Can GSK’s Gepotidacin Priority FDA Review and Strategic Acquisitions Accelerate Its Antibiotic and Specialty…
Key Highlights: FDA Priority Review of Gepotidacin for GonorrhoeaGSK submitted a supplemental New Drug Application for gepotidacin, targeting…
Why Is Eli Lilly’s 2025 Outlook Soaring Despite Orforglipron’s Late-Stage Trial Falling Short?
Key Highlights: Strong Sales Growth and Raising GuidanceEli Lilly posted impressive Q2 2025 earnings surpassing estimates, largely on…
Why Could Novartis’ Ianalumab, With Dual Mechanism of B-Cell Depletion and BAFF-R Inhibition, Revolutionize Treatment for Sjögren’s Disease?
Key Highlights: Positive Phase III Results Confirm Efficacy in Sjögren’s DiseaseThe NEPTUNUS-1 (275 patients) and NEPTUNUS-2 (504 patients)…
Can AstraZeneca’s $50 Billion U.S. Investment and Drug Price Cuts Signal a New Era…
Key Highlights: Strategic Response to U.S. Pricing PressuresAstraZeneca CEO Pascal Soriot announced proactive proposals for U.S. drug price…
How Google Med-Gemini’s “Basilar Ganglia” AI Hallucination Signal a Wake-Up Call for Safer AI in Medical Diagnostics?
Key Highlights: AI Hallucination: The “Basilar Ganglia” ErrorGoogle’s Med-Gemini suite, designed to summarize health data and generate radiology…
Can XtalPi & DoveTree’s $6 Billion AI Partnership Transform “Undruggable” Disease Targets in Biopharma…
Key Highlights: Strategic Overview: Industry’s Largest AI-Pharma CollaborationThis collaboration—one of the biggest in AI-driven drug discovery—combines XtalPi’s robust…